Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1168-1171

  Rosso, Raffaella ^a   Di Biagio, Antonio ^a   Dentone, Chiara ^a   Gattinara, Guido Castelli ^b   Martino, Alessandra Maria ^b   Viganò, Alessandra ^c   Merlo, Marzia ^c   Giaquinto, Carlo ^d   Rampon, Osvalda ^d   Bassetti, Matteo ^a   Gatti, Giorgio ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Pharmacokinetics; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PILOT STUDY; STATISTICAL SIGNIFICANCE; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; PLASMA; PRESCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PLASMA; PYRIMIDINONES; RITONAVIR;

EID: 33749174135     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl136     Document Type: Article

References (18)

1. de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284: 190-7.
2. Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-8.
3. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2: 93-102.
4. Gibb DIM, Duong T, Tookey PA et al. Decline in mortality, AIDS and hospital admission in perinatally HIV-1 infected children in the UK and Ireland. BMJ 2003; 327: 1019-25.
5. Cvetkovic R, Goa K. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
6. Resino S, Bellon JM, Ramos JT et al. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: A prospective cohort study. J Antimicrob Chemother 2004; 54: 921-31.
7. Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216-24.
8. Ramos JT, De Jose MI, Duenas J et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J 2005; 24: 867-73.
9. US DHHS. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. http://aidsinfo.nih.gov/guidelines (17 November 2005, date last accessed).
10. Sharland M, Blanche S, Castelli G et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 Suppl 2: 61-86.
11. Boffito M, Acosta E, Burger D et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 2005; 10: 469-77.
12. Eron JJ, Feinberg J, Kessler HA et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004; 189: 265-72.
13. Kaletra [Summary of product characteristics]. Chicago, IL: Abbott, 2000.
14. Verweel G, van der Lee MJ, Burger DM et al. 6-Month follow-up of once-daily lopinavir/ritonavir in HIV-infected children. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 769, p. 348. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
15. Bergshoeff AS, Fraaij PL, Ndagijimana J et al. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J Acquir Immune Defic Syndr 2005; 39: 63-8.
16. Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-9.
17. Molla A, Vasavanonda S, Kumar G et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250: 255-62.
18. Boffito M, Acosta E, Burger D et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Ther 2005; 10: 375-92.